Ocular Therapeutix Statistics
Share Statistics
Ocular Therapeutix has 157.22M shares outstanding. The number of shares has increased by 35.77% in one year.
| Shares Outstanding | 157.22M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.67% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 135.64M |
| Failed to Deliver (FTD) Shares | 17 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 12.67M, so 8.06% of the outstanding shares have been sold short.
| Short Interest | 12.67M |
| Short % of Shares Out | 8.06% |
| Short % of Float | 9.36% |
| Short Ratio (days to cover) | 9.68 |
Valuation Ratios
The PE ratio is -4.41 and the forward PE ratio is -10.39.
| PE Ratio | -4.41 |
| Forward PE | -10.39 |
| PS Ratio | 6.09 |
| Forward PS | 18.2 |
| PB Ratio | 3.91 |
| P/FCF Ratio | -4.66 |
| PEG Ratio | n/a |
Enterprise Valuation
Ocular Therapeutix Inc. has an Enterprise Value (EV) of 243.46M.
| EV / Earnings | -3.02 |
| EV / Sales | 4.17 |
| EV / EBITDA | -3.67 |
| EV / EBIT | -2.96 |
| EV / FCF | -3.19 |
Financial Position
The company has a current ratio of 6.66, with a Debt / Equity ratio of 0.84.
| Current Ratio | 6.66 |
| Quick Ratio | 6.59 |
| Debt / Equity | 0.84 |
| Total Debt / Capitalization | 45.64 |
| Cash Flow / Debt | -0.92 |
| Interest Coverage | -7.27 |
Financial Efficiency
Return on equity (ROE) is -0.89% and return on capital (ROIC) is -47.2%.
| Return on Equity (ROE) | -0.89% |
| Return on Assets (ROA) | -0.32% |
| Return on Capital (ROIC) | -47.2% |
| Revenue Per Employee | 218.89K |
| Profits Per Employee | -302.38K |
| Employee Count | 267 |
| Asset Turnover | 0.23 |
| Inventory Turnover | 2.29 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 120.61% in the last 52 weeks. The beta is 1.26, so Ocular Therapeutix 's price volatility has been higher than the market average.
| Beta | 1.26 |
| 52-Week Price Change | 120.61% |
| 50-Day Moving Average | 10.06 |
| 200-Day Moving Average | 8.22 |
| Relative Strength Index (RSI) | 40.38 |
| Average Volume (20 Days) | 1.18M |
Income Statement
In the last 12 months, Ocular Therapeutix had revenue of $58.44M and earned -$80.74M in profits. Earnings per share was $-1.09.
| Revenue | 58.44M |
| Gross Profit | 53.16M |
| Operating Income | -82.38M |
| Net Income | -80.74M |
| EBITDA | -66.42M |
| EBIT | -82.38M |
| Earnings Per Share (EPS) | -1.09 |
Balance Sheet
The company has $195.81M in cash and $83.39M in debt, giving a net cash position of $112.42M.
| Cash & Cash Equivalents | 195.81M |
| Total Debt | 83.39M |
| Net Cash | 112.42M |
| Retained Earnings | -697.58M |
| Total Assets | 490.37M |
| Working Capital | 436.65M |
Cash Flow
In the last 12 months, operating cash flow was -$70.23M and capital expenditures -$6.09M, giving a free cash flow of -$76.32M.
| Operating Cash Flow | -70.23M |
| Capital Expenditures | -6.09M |
| Free Cash Flow | -76.32M |
| FCF Per Share | -0.96 |
Margins
Gross margin is 90.96%, with operating and profit margins of -140.96% and -138.14%.
| Gross Margin | 90.96% |
| Operating Margin | -140.96% |
| Pretax Margin | -138.14% |
| Profit Margin | -138.14% |
| EBITDA Margin | -113.64% |
| EBIT Margin | -140.96% |
| FCF Margin | -130.59% |
Dividends & Yields
OCUL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -12.57% |
| FCF Yield | -5.6% |
Analyst Forecast
The average price target for OCUL is $15, which is 73% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 73% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 3.77 |
| Piotroski F-Score | 3 |